# Systemic glucocorticoid pharmacology audit

Status: verified locally, 2026-09-24. Started after autoimmune-foundations commit 559d920. Earlier entries below describe intermediate review state; the closure entry supersedes their pending items.

## Chapter closure finding

The whole-chapter check identified an omitted overlapping module: `systemic-glucocorticoid-pharmacology`, number 97. It has 11 lessons and a 180-item generated assessment bank. Existing chapter mapping included adrenal pharmacology but omitted this actual module. Chapter 46 cannot be closed until it is reconciled. Printed 655/PDF663 is the next unit divider, not additional chapter clinical content; chapter clinical pages end at printed654/PDF662.

Read source definitions for all 11 figures and most lesson text; a long combined output truncated the hpa-risk passage, so that passage and final integrated read remain outstanding. Inspected generator logic and selected bank concepts; full 45-concept review and all alternatives remain pending. Generator currently makes four variants per concept, unrelated concept distractors and answer index0, with an artificial100-question minimum. Replace with original focused cases after complete concept review; do not treat structural validity as clinical evidence.

## Initial evidence and corrections

Read current 2024 joint endocrine recommendation summary and targeted full-guideline Table1, R2.7 testing rationale and R2.12 mineralocorticoid rationale. Full text accessible at https://academic.oup.com/jcem/article/109/7/1657/7667842 . This is not a complete guideline read.

- The module's dexamethasone/betamethasone0.5mg equivalents are supported by guideline Table1, not simply wrong. Added explicit source attribution and contrasted RxPrep dexamethasone0.75mg/betamethasone0.6mg; a consistent named table is required. Added the source cue to the figure and bank. The original methylprednisolone32mg to prednisone40mg calculation remains correct:32/4*5=40.
- Added8-9AM recovery sampling and clinician-directed hold of at least24hours for appropriate short-acting therapy, with a separate dexamethasone plan. Do not delay stress coverage for a test. Assessment case now specifies proper collection context.
- Qualified hyperkalemia: aldosterone generally remains intact in glucocorticoid-induced insufficiency, unlike primary adrenal failure. Do not teach hyperkalemia as its characteristic mechanism.
- Added the greater-than10kg context for CDC's20mg/day live-vaccine criterion to lesson and bank; updated the CDC reference URL. This is consistent with the directly read CDC passage in the autoimmune-foundations audit.

## Remaining work

Finish every lesson/concept/answer/rationale read; current drug-label, chemistry, ADA2026 and ACR source reconciliation; focused bank replacement and coverage; independently check all numbers; inspect11figures and learner interactions on desktop/mobile; scoring/reset/readability and final build; update statuses only after closure. No module completion, commit, push or deployment claimed for these edits. No source-book files are in public assets or version control.

## Assessment and guideline pass

Read the remaining hpa-risk lesson and all 45 concept records. Replaced the180-item four-variant generator and unrelated alternatives with45focused cases, individually authored alternatives and rotating answer positions. Removed the arbitrary100-item minimum. Initial structural audit returned no hard errors or source gaps; final integrated coverage review is still required.

Read ACR2022 GIOP summary pages1-4's risk-assessment and initial-treatment recommendations (July2023 revision): https://assets.contentstack.io/v3/assets/bltee37abb6b278ab2c/blt8c68fa62e5f70069/giop-guideline-summary-2022.pdf . Existing adult assessment threshold agrees; added direct reference. No detailed osteoporosis drug regimen imported from this overview.

Direct ADA2026 page returned403, but the publisher's indexed Glucocorticoid Therapy passage explicitly describes normal/mild fasting elevations with afternoon/evening rises after morning prednisone/prednisolone and matching insulin strategy to steroid duration. This supports the module's retained timing claim. No full ADA article read claimed. Indexed Endotext mechanism/SAR passage retrieved; complete chemistry reconciliation remains pending.

Clarified that an existing high glucocorticoid dose can already satisfy stress coverage rather than automatically adding more; this agrees with the joint guideline Table8 passages read during the previous source pass. Strengthened exogenous-Cushing teaching to the guideline's assumption of glucocorticoid-induced insufficiency. Embedded short-course case now excludes preceding chronic exposure; embedded cortisol case now specifies collection/hold context.

Still open: primary chemistry and formulation sources, current label safety/interaction claims, final integrated45-case and all-lesson review,11figures and desktop/mobile interactions, scoring/reset/readability, final build. No verified/commit claim for this module.


## Final reconciliation and local verification

Reviewed all 11 lessons and embedded checks, all 11 figure definitions and desktop/mobile renders, and every emitted question, answer, alternative and explanation. Final bank: 48 focused cases. The 45 original concepts remain covered, with three new infection-safety cases. The structural size advisory is intentionally resolved by clinical coverage, not a question quota. Bone/tissue safety has two bank cases plus its embedded check and dedicated teaching; the figure and lesson cover bone, muscle, eyes, skin and growth.

Additional corrections:
- Qualified C16 chemistry: hydroxyl and methyl substitutions do not have identical potency effects. Added named formulation examples and the prohibition on IV Depo-Medrol acetate suspension.
- Added the greater-than10kg qualification to the second CDC threshold mention.
- Specified general/regional anesthesia in the stress lesson and figure; not every local-anesthetic procedure requires parenteral coverage.
- Taught the specialist-referral rule already assessed by the bank: nonrecovery after one year at physiologic dosing, or history of adrenal crisis.
- Added product-specific infection preflight and exposure precautions, with HBV, Strongyloides and varicella cases. These are not a universal screening panel for every brief steroid course.
- Removed the unsupported source-line claim of a complete medicinal-chemistry synthesis.

Source evidence completed:
- Endotext 2018 publisher PDF, mechanism and synthetic-glucocorticoid passages on PDF pages2-5: https://www.endotext.org/wp-content/uploads/pdfs/glucocorticoid-therapy-and-adrenal-suppression.pdf . Used for mechanism/SAR, not current taper rules.
- Hobson et al., RSC Medicinal Chemistry2024 author manuscript, abstract, introduction, receptor-construct methods and binding-results/conclusion passages: https://pubs.rsc.org/en/content/getauthorversionpdf/D3MD00540B . Engineered human GR-ligand structure supports oxygen-group binding teaching; it is not a native clinical efficacy study. No proprietary figure reproduced. Earlier porcine-GR paper and unavailable Bledsoe PDF were not used as human structural proof.
- Solu-Medrol current label (updated June25,2026), description, clinical pharmacology, route and contraindication passages: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7271310c-7764-4812-aa30-a5e90987c7a9 . Depot restriction confirmed from indexed manufacturer-label packaging: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bf1b104d-85cb-414d-a366-78068c82c883 . No full injectable-label review claimed.
- Medrol warning, precaution, interaction, adverse-effect and pregnancy passages: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1d875fdc-c13c-7391-e063-6294a90a0c84 . Infection, psychiatric, ocular, growth and other retained safety claims reconciled. Its legacy secondary-insufficiency mineralocorticoid wording conflicts with the2024 joint endocrine recommendation; retained current guidance against routine fludrocortisone for glucocorticoid-induced insufficiency.
- Indexed fluticasone HFA label interaction passage confirms ritonavir-associated systemic exposure, Cushing syndrome and adrenal suppression: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=faaa1436-dafb-4f65-b062-b51b902f43c5&type=display . Did not use obsolete product taper schedules.
- Current joint endocrine, CDC, ACR and indexed ADA evidence and reading limits remain documented above. Numerical review includes32/4*5=40mg; source-specific dexamethasone/betamethasone equivalents; separate adrenal, vaccine and bone thresholds; cortisol3<5mcg/dL and recovery bands.

Validation on final content:
- Structural audit:48questions, no hard errors or source gaps. Every case and its alternatives read; all11lesson targets covered.
- Production build passed,557pages generated. Logs `/private/tmp/gc-audit-build-final.log` and `/private/tmp/gc-structural-final.log`.
- All11sections: navigation, embedded-check feedback, review anchors, one figure per lesson, HTTP200, no horizontal overflow or page errors at1440x1000 and390x844.
- All22figure captures inspected. Some original element captures include the fixed tools control; separate scroll-position readability checks confirmed all teaching words can be brought unobscured into view. The final revised stress figure was recaptured and inspected at both sizes.
- Final practice scoring10/10 and reset/new-attempt behavior passed at both sizes. This is UI scoring verification; clinical review covered all48cases separately.
- Final scrolling word-hit check:2048lesson/figure words at each size, no obscured words at the tested reading positions. Screenshot inspection confirmed readable text.
- Diff whitespace check passed. No deployment or remote-push claim. Book/extracts remain outside version control.

Module review is complete locally. Chapter46 still requires whole-chapter closure; the full curriculum goal remains active. This is an evidence-based content audit, not independent pharmacist certification.
